AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20698844 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% DHEA cream
Number of subjects: 75
Study 20698844 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% DHEA cream
Number of subjects: 75
Study 20698844 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% DHEA cream
Number of subjects: 75
Study 20698844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 16940735 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional tasks exercise programme (function group)
Number of subjects: 98
Study 16940735 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise programme (resistance group)
Number of subjects: 98
Study 16940735 — intervention group
Group type: COMPARATOR
Intervention: Normal activity group (control group)
Number of subjects: 98
Study 16750466 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5%
Number of subjects: 29
Study 16750466 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%
Number of subjects: 29
Study 16750466 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 29
Study 15573827 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group (EG)
Number of subjects: 114
Study 15573827 — intervention group
Group type: COMPARATOR
Intervention: Control group (CoG)
Number of subjects: 114
Study 11236238 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day)
Number of subjects: 18
Study 11236238 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day)
Number of subjects: 18
Study 11236238 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 18
Study 8641599 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous fluids (s.c.)
Number of subjects: 60
Study 8641599 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluids (i.v.)
Number of subjects: 60
Study 1634173 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical combination preparation containing standardized leech extract, polidocanol and allantoin
Number of subjects: 80
Study 1634173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 6095468 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 3 mg/kg/d for 1 week
Number of subjects: 42
Study 6095468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gammaglobulin 100 mg/kg on 2 successive days
Number of subjects: 42
Study 6095468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 1000 mg 3 times a day for 1 week
Number of subjects: 42
Study 6095468 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 42
Study 31810797 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib 1.5 mg orally once daily in 4-week cycles
Number of subjects: 350
Study 31810797 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 400 mg orally twice daily continuously
Number of subjects: 350
Study 31810797 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib
Number of subjects: 350
Study 31810797 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 350
Study 30006860 — intervention group
Group type: EXPERIMENTAL
Intervention: n-back training (experimental condition)
Number of subjects: 52
Study 30006860 — intervention group
Group type: COMPARATOR
Intervention: no-contact control condition
Number of subjects: 52
Study 28678953 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide followed by the application of CPP-ACPF
Number of subjects: 60
Study 28678953 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide followed by the application of NovaMin
Number of subjects: 60
Study 28678953 — intervention group
Group type: COMPARATOR
Intervention: 35% hydrogen peroxide
Number of subjects: 60
Study 25944156 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g topical TXA
Number of subjects: 150
Study 25944156 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g intravenous TXA
Number of subjects: 150
Study 25944156 — intervention group
Group type: COMPARATOR
Intervention: Routine hemostasis (control group)
Number of subjects: 150
Study 24074484 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose aripiprazole (3mg/day)
Number of subjects: 586
Study 24074484 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible dose aripiprazole (3-15 mg/day)
Number of subjects: 586
Study 24074484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study 22110105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium excretion > 7 g/day
Number of subjects: 28880
Study 22110105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium excretion < 3 g/day
Number of subjects: 28880
Study 22110105 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium excretion 1.5-1.99 g/day
Number of subjects: 28880
Study 22110105 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium excretion 2-2.49 g/day
Number of subjects: 28880
Study 22110105 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium excretion 2.5-3 g/day
Number of subjects: 28880
Study 22110105 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium excretion > 3 g/day
Number of subjects: 28880
Study 22110105 — intervention group
Group type: COMPARATOR
Intervention: Sodium excretion 4-5.99 g/day
Number of subjects: 28880
Study 19619703 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRB2 rs180088
Number of subjects: 20806
Study 19619703 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI1 rs1799768
Number of subjects: 20806
Study 19619703 — intervention group
Group type: EXPERIMENTAL
Intervention: C5 rs17611
Number of subjects: 20806
Study 19619703 — intervention group
Group type: EXPERIMENTAL
Intervention: CTLA4 rs5742909
Number of subjects: 20806
Study 19619703 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRB2 rs180088 (postmenopausal women)
Number of subjects: 20806
Study 19619703 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI1 rs1799768 (postmenopausal women)
Number of subjects: 20806
Study 19619703 — intervention group
Group type: EXPERIMENTAL
Intervention: SCNN1A rs5742912 (postmenopausal women)
Number of subjects: 20806
Study 19619703 — intervention group
Group type: EXPERIMENTAL
Intervention: IL1A rs1800587 (postmenopausal women)
Number of subjects: 20806
Study 19619703 — intervention group
Group type: EXPERIMENTAL
Intervention: AGTR1 rs5186 (postmenopausal women)
Number of subjects: 20806
Study 19619703 — intervention group
Group type: EXPERIMENTAL
Intervention: SCNN1A rs5742912 (current users of hormone therapy)
Number of subjects: 20806
Study 17192690 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate spray
Number of subjects: 60
Study 17192690 — intervention group
Group type: COMPARATOR
Intervention: Control (no topical agent)
Number of subjects: 60
Study 14559694 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (30 degrees Celsius)
Number of subjects: 20
Study 14559694 — intervention group
Group type: COMPARATOR
Intervention: Moderate hypothermia (26 degrees Celsius)
Number of subjects: 20
Study 14559694 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups during CPB
Number of subjects: 20
Study 11021121 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A (Dk = 140) worn for up to 30 days and nights
Number of subjects: 0
Study 11021121 — intervention group
Group type: COMPARATOR
Intervention: Etafilcon A (Dk = 28) worn for up to 7 days and 6 nights
Number of subjects: 0
Study 8612379 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg orally three times a day for 2 days
Number of subjects: 10
Study 8612379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1315664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention communities
Number of subjects: 11
Study 1315664 — intervention group
Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 11
Study 6426754 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency coagulation of the Gasserian ganglion under neuroleptanalgesia and intermittent ultrashort‐acting barbiturate anaesthesia
Number of subjects: 12
Study 6426754 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency coagulation of the Gasserian ganglion
Number of subjects: 12
Study 6426754 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin during current generation
Number of subjects: 12
Study 6426754 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous thermocoagulation of the Gasserian ganglion
Number of subjects: 12
Study 6426754 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and protection during procedure
Number of subjects: 12
Study 31801477 — intervention group
Group type: EXPERIMENTAL
Intervention: Childbirth Experience Questionnaire 2.0 (Farsi version)
Number of subjects: 500
Study 29122195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit condition (balanced demand-skill level)
Number of subjects: 0
Study 29122195 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional N-Back task (high mental workload)
Number of subjects: 0
Study 29122195 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-demand level (boredom)
Number of subjects: 0
Study 29122195 — intervention group
Group type: EXPERIMENTAL
Intervention: High-demand level (anxiety)
Number of subjects: 0
Study 26584404 — intervention group
Group type: EXPERIMENTAL
Intervention: 4g day(‐1) paracetamol
Number of subjects: 0
Study 26584404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24197757 — intervention group
Group type: EXPERIMENTAL
Intervention: BCS+WBI (arm 1: 373 patients)
Number of subjects: 749
Study 24197757 — intervention group
Group type: COMPARATOR
Intervention: BCS alone (arm 2: 376 patients)
Number of subjects: 749
Study 22101392 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring Systems (MEMS)
Number of subjects: 0
Study 22101392 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMS
Number of subjects: 0
Study 20955571 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage and drainage (LOLA-arm)
Number of subjects: 344
Study 20955571 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's procedure or sigmoidectomy with primary anastomosis (LOLA-arm)
Number of subjects: 344
Study 20955571 — intervention group
Group type: EXPERIMENTAL
Intervention: Hartmann's procedure (DIVA-arm)
Number of subjects: 344
Study 20955571 — intervention group
Group type: COMPARATOR
Intervention: Resection with primary anastomosis (DIVA-arm)
Number of subjects: 344
Study 20955571 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (secondary endpoints)
Number of subjects: 344
Study 17685727 — intervention group
Group type: COMPARATOR
Intervention: Athletic Shoe (AS)
Number of subjects: 14
Study 17685727 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridian Elyte (MS)
Number of subjects: 14
Study 16362843 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline with late partial sleep deprivation
Number of subjects: 37
Study 16362843 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline with bright light therapy
Number of subjects: 37
Study 16362843 — intervention group
Group type: COMPARATOR
Intervention: Sertraline monotherapy
Number of subjects: 37
Study 11828949 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU/kg of r‐huEPO
Number of subjects: 72
Study 11828949 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU/kg of r‐huEPO
Number of subjects: 72
Study 11828949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 11828949 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐huEPO (both doses)
Number of subjects: 72
Study 11828949 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐huEPO
Number of subjects: 72
Study 9564184 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine 100 mg
Number of subjects: 64
Study 9564184 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine 75 mg
Number of subjects: 64
Study 9564184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 7846198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsapirone 20 mg
Number of subjects: 15
Study 7846198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3053609 — intervention group
Group type: EXPERIMENTAL
Intervention: fenfluramine
Number of subjects: 28
Study 3053609 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 29497863 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid lowering treatment (specific intervention not detailed)
Number of subjects: 0
Study 27919404 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT+
Number of subjects: 92
Study 27919404 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 92
Study 26378067 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.08 mg/kg oxycodone (Group O)
Number of subjects: 54
Study 26378067 — intervention group
Group type: COMPARATOR
Intervention: 1 µg/kg fentanyl (Group F)
Number of subjects: 54
Study 23296279 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate for 24 weeks
Number of subjects: 64
Study 23296279 — intervention group
Group type: COMPARATOR
Intervention: Other antihypertensive drugs (non-nitrate group)
Number of subjects: 64
Study 23296279 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation
Number of subjects: 64
Study 21484744 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia ceramic head, polyethylene cup (Group A)
Number of subjects: 205
Study 21484744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt‐Chrome‐Molybdenum head and cup (Group B)
Number of subjects: 205
Study 21484744 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia ceramic head, polyethylene moulded on the Titanium shell of the Asian cup (Group C)
Number of subjects: 205
Study 21484744 — intervention group
Group type: EXPERIMENTAL
Intervention: Alumina head and cup (Group D)
Number of subjects: 205
Study 18293149 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO before 12:00 h (n=9)
Number of subjects: 22
Study 18293149 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO after 18:00 h (n=6)
Number of subjects: 22
Study 18293149 — intervention group
Group type: EXPERIMENTAL
Intervention: PROT after 18:00 h (n=7)
Number of subjects: 22
Study 18293149 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 22
Study 16812927 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent, family-based programs for children aged 5-12 years
Number of subjects: 0
Study 16812927 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent, school-based programs for adolescents
Number of subjects: 0
Study 16812927 — intervention group
Group type: COMPARATOR
Intervention: Community-based interventions
Number of subjects: 0
Study 14633813 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (insulin aspart, metformin, rosiglitazone)
Number of subjects: 16
Study 14633813 — intervention group
Group type: COMPARATOR
Intervention: Control (NPH or MIX insulin)
Number of subjects: 16
Study 11077130 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release moxonidine 0.9 mg bid
Number of subjects: 25
Study 11077130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9401362 — intervention group
Group type: EXPERIMENTAL
Intervention: Near fatal asthma patients (n=17)
Number of subjects: 34
Study 9401362 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=17)
Number of subjects: 34
Study 8354296 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate suspension given b.i.d. for seven days
Number of subjects: 311
Study 8354296 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate suspension given t.i.d. for seven days
Number of subjects: 311
Study 8354296 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups (b.i.d. and t.i.d.)
Number of subjects: 311
Study 2885572 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-density lipoproteins (IDL)
Number of subjects: 57
Study 2885572 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine treatment
Number of subjects: 57
Study 2885572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 2885572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratios of HDL-cholesterol to total-cholesterol or LDL-cholesterol
Number of subjects: 57
Study 30887126 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual well-being
Number of subjects: 190
Study 30887126 — intervention group
Group type: COMPARATOR
Intervention: Secure attachment
Number of subjects: 190
Study 28241025 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based CBT with therapist support (LITG)
Number of subjects: 296
Study 28241025 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based CBT without therapist support (TSG)
Number of subjects: 296
Study 28241025 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 296
Study 26492167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation treatment (coagulation) in Group A (small endometriomas)
Number of subjects: 48
Study 26492167 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision treatment in Group A (small endometriomas)
Number of subjects: 48
Study 26492167 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision treatment in Group B (large endometriomas)
Number of subjects: 48
Study 26492167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation treatment (coagulation) in Group B (large endometriomas)
Number of subjects: 48
Study 24008921 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hyperventilation (partial pressure of carbon dioxide at 30 mmHg)
Number of subjects: 30
Study 24008921 — intervention group
Group type: COMPARATOR
Intervention: Moderate hypoventilation (partial pressure of carbon dioxide at 50 mmHg)
Number of subjects: 30
Study 21157390 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss Supplement (WLS)
Number of subjects: 24
Study 21157390 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 24
Study 19412140 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace intervention
Number of subjects: 196
Study 18097108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 17 beta‐estradiol (300 microg/day)
Number of subjects: 80
Study 18097108 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol (50 microg/day)
Number of subjects: 80
Study 18097108 — intervention group
Group type: COMPARATOR
Intervention: Control (Vaginal progesterone gel twice weekly)
Number of subjects: 80
Study 15066049 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 120
Study 15066049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 12488664 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course ciprofloxacin (15 mg/kg every 12 h for 3 days followed by placebo for 2 days)
Number of subjects: 253
Study 12488664 — intervention group
Group type: COMPARATOR
Intervention: Standard course ciprofloxacin (15 mg/kg every 12 h for 5 days)
Number of subjects: 253
Study 12488664 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (short and standard course ciprofloxacin)
Number of subjects: 253
Study 9400449 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection of 10 micrograms alprostadil plus genital plus audiovisual sexual stimulation
Number of subjects: 20
Study 9400449 — intervention group
Group type: COMPARATOR
Intervention: Re-dosing of 10 micrograms alprostadil
Number of subjects: 20
Study 7654128 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride 50 mg/d
Number of subjects: 33
Study 7654128 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride 100 mg (single dose)
Number of subjects: 33
Study 7654128 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride 150 mg/d
Number of subjects: 33
Study 7654128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 2667598 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of CGP 38 560 A at doses of 50, 125, and 250 micrograms kg‐1
Number of subjects: 0
Study 2667598 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of CGP 38 560 A at doses of 50, 100, and 200 mg
Number of subjects: 0
Study 933252 — intervention group
Group type: EXPERIMENTAL
Intervention: Marihuana
Number of subjects: 30
Study 933252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7001331 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidarabine therapy
Number of subjects: 56
Study 7001331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 31629831 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg, acute administration)
Number of subjects: 0
Study 31629831 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 31752847 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic Navigation Bronchoscopy (ENB)
Number of subjects: 48
Study 31752847 — intervention group
Group type: COMPARATOR
Intervention: Conventional bronchoscopy on phantom
Number of subjects: 48
Study 28389705 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (3.0/1.5 mU kg‐1 min‐1) under hyperglycaemic ketotic conditions (KET)
Number of subjects: 9
Study 28389705 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion (3.0/1.5 mU kg‐1 min‐1) under euglycaemic conditions (CTR)
Number of subjects: 9
Study 25884922 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 week CBT group guided self-help intervention
Number of subjects: 46
Study 25884922 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Delayed Access Control)
Number of subjects: 46
Study 23122669 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX 0.5 μg/kg (group D)
Number of subjects: 60
Study 23122669 — intervention group
Group type: COMPARATOR
Intervention: Placebo bolus (group C)
Number of subjects: 60
Study 21183500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac troponin I (cTnI) ≥0.03 ng/mL
Number of subjects: 4352
Study 21183500 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro B-type natriuretic peptide (NT-proBNP) ≥400 pg/mL
Number of subjects: 4352
Study 21183500 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP) ≥15 mg/L
Number of subjects: 4352